New startups, fundings, mergers, clinical trials, partnerships – GeekWire

[ad_1]

A protein (purple) interacting with a small molecule, a potential drug (green), visualized in Charm Therapeutics’ DragonFold tool. (Charm Image)

Here’s a rundown of life sciences and health news across the Pacific Northwest this week.

Partnerships:

  • DNA sequencing companies TwinStrand Biosciences, based in Seattle, and Singular Genomics have paired up to develop ultra-sensitive tests to detect rare gene variants. One application is detection of “minimal residual disease” in cells and tumor DNA in the bloodstream.
  • Seattle’s Umoja Biopharma and TreeFrog Therapeutics are combining technology to make new cell therapies from human induced pluripotent stem cells, blank-slate cells that can be nudged into different cell types. Umoja has a way to turn these cells into therapeutic immune cells, and TreeFrog can grow them in large amounts.  

American Society of Clinical Oncology (ASCO) abstracts:

Clinical trials:

  • People from age six months to 49 years will be assessed in a study asking how well COVID-19 vaccines protect against illness, especially in children, and how the immune system responds after infection. The multi-center study will enroll 3,500 people in the Seattle and Portland areas.
  • Cell therapy company Sonoma Biotherapeutics has the green light from the U.S. Food and Drug Administration for an early-stage trial of its biologic SBT115301. SBT115301 is designed to eliminate highly active immune cells present in autoimmune and inflammatory diseases, in preparation for treatment with cells derived from immune-calming “regulatory” T cells.

Publications:

  • Researchers at Seattle Children’s Research Institute and their colleagues assessed isoflurane, a common anesthetic. The gas inhibits a key protein complex in mitochondria, the cell’s energy-producing factories, leading to effects on neurons.
  • Baker, head of the UW’s Institute for Protein Design, and his colleagues penned a review article in Nature exploring how to design efficient enzymes from scratch.

New manufacturing center:

  • Swiss biomanufacturing giant Lonza has expanded its facility in Bend, Ore., adding a new center focused on improving delivery of oral or inhaled small molecules.

Closed for business:

  • Washington state attorney general Bob Ferguson won $500,000 for people who had paid for unproven stem cell treatments from a company that ran the Seattle Stem Cell Center, which is no longer allowed to market such treatments.

Events and deadlines:



[ad_2]

Source link